Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Proteomic landscape of histiocytic neoplasms: Advancing precision biomarkers, molecular mechanism, and targeted therapies

Refael Meyuchas, Tamar Ziv, Mali Salmon-Divon, Ofer Shpilberg, May Basood, Benjamin Durham, Matthias Papo, Fleur Cohen-Aubart, Omar Abdel-Wahab, Eli Diamond, Julien Haroche, Oshrat Hershkovitz-Rokah

Blood (2025) 146 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2025-1211

Published: 2025

Journal Articles

MAPK pathway-driven metabolic-inflammatory axis in AL amyloidosis

Tal Zvida-Bloch, Eli Muchtar, Ifat Abramovich, Bella Agranovich, Mali Salmon-Divon, May Basood, Benjamin Bender, Adrian Duek, Merav Leiba, Moshe Gatt, Wilson Gonsalves, Angela Dispenzieri, Ofer Shpilberg, Oshrat Hershkovitz-Rokah

Blood (2025) 146 (Supplement 1): 5709.

https://doi.org/10.1182/blood-2025-5709

Published: 2025

Journal Articles

Clinical presentation and prognosis in erdheim-chester disease: Analysis of an international cohort of 1044 patients within the ecdga network

Blood (2025) 146 (Supplement 1): 192.

https://doi.org/10.1182/blood-2025-192

Published: 2025

Journal Articles

Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications

Tal Zvida-Bloch, Eli Muchtar, Mali Salmon-Divon, Angela Dispenzieri, Benjamin Bender, Adrian Duek, Merav Leiba, Moshe E Gatt, Ofer Shpilberg, Oshrat Hershkovitz-Rokah

Blood (2024) 144 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2024-206682

Published: 2024

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Blood (2024) 144 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2024-202392

Published: 2024

Journal Articles

Deciphering the Epigenetic Landscape in Histiocytic Neoplasms

Mali Salmon-Divon, Refael Meyuchas, Jamal Benhamida, Ofer Shpilberg, Roei D. Mazor, Mariko Yabe, Kseniya Petrova-drus, Omar Abdel-Wahab, Eli L. Diamond, Oshrat Hershkovitz-Rokah

Blood (2023) 142 (Supplement 1): 1161.

https://doi.org/10.1182/blood-2023-185965

Published: 2023

Journal Articles

Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Olga Kersy, Mali Salmon-Divon, Maria Gomes da Silva, Ana Filipa Moita, Jose Cabecadas, Pavel Klener, Jr., Marek Trněný, May Basood, Ofer Shpilberg, Oshrat Hershkovitz-Rokah

Blood (2022) 140 (Supplement 1): 3109–3110.

https://doi.org/10.1182/blood-2022-169574

Published: 2022

Journal Articles

Non-Coding RNAs Regulate Novel Signaling Pathways in AL Amyloidosis That Are Targetable By BCL2, PI3K and MEK Inhibitors

Tal Zvida, Eli Muchtar, Mali Salmon-Divon, Angela Dispenzieri, Hila Fishov, Claudio Schneider, Benjamin Bender, Adrian Duek, Merav Leiba, Ofer Shpilberg, Oshrat Hershkovitz-Rokah

Blood (2022) 140 (Supplement 1): 7074–7075.

https://doi.org/10.1182/blood-2022-164964

Published: 2022

Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Blood (2022) 140 (Supplement 1): 4426–4427.

https://doi.org/10.1182/blood-2022-164572

Published: 2022

Journal Articles

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2022) 140 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2022-163018

Published: 2022

Journal Articles

The Role of Non-Coding RNAs in the Pathogenesis of AL Amyloidosis

Hila Fishov, Eli Muchtar, Mali Salmon-Divon, Angela Dispenzieri, Ofer Shpilberg, Oshrat Rokah

Blood (2021) 138 (Supplement 1): 2659.

https://doi.org/10.1182/blood-2021-150828

Published: 2021

Journal Articles

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139670

Published: 2020

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Ran Weissman, MSc, Nir Pilar, MD, Benjamin H Durham, MD BS, Michelle Ki, BSc, Roei D Mazor, MD, Omar I Abdel-Wahab, MD, Noam Shomron, PhD, Ofer Shpilberg, MD MPH, Eli L Diamond, MD, Oshrat Rokah, PhD

Blood (2018) 132 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2018-99-112388

Published: 2018

Journal Articles

Eltrombopag for Enhancement of Platelet Engraftment in Patients Undergoing Allogeneic Cord Blood Transplantation

Oren Pasvolsky, Liat Shargian, MD, Uri Rozovski, Ron Ram, MD, Michael Y. Shapira, MD, Moshe Israeli, Liat Vidal-Fisher, MD MSc, Ofer Shpilberg, MD MPH, Pia Raanani, Moshe Yeshurun

Blood (2018) 132 (Supplement 1): 2092.

https://doi.org/10.1182/blood-2018-99-116048

Published: 2018

Journal Articles

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Tanya Mashiach, MSc, Elinor Barzilai, BSc, Abraham Korenberg, MD, Luiza Akria, MD, Tamar Tadmor, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Olga Kagna, MD, Rosa Ruchlemer, MD, Neta Goldschmidt, MD, Netanel A. Horowitz, MD, David Lavie, MD, Dina Ben-Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2016) 128 (22): 3001.

https://doi.org/10.1182/blood.V128.22.3001.3001

Published: 2016

Journal Articles

Bendamustine for Patients with Indolent Lymphoma an Updated Meta-Analysis of Randomized Controlled Trials (RCT)

Liat Vidal, MDMSc, Liat Shargian, MD, Ofer Shpilberg, MD MPH, Ron Ram, MD, Pia Raanani, MD, Ronit Gurion, MD, Anat Gafter, MD

Blood (2015) 126 (23): 3963.

https://doi.org/10.1182/blood.V126.23.3963.3963

Published: 2015

Journal Articles

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

Blood (2015) 126 (23): 28.

https://doi.org/10.1182/blood.V126.23.28.28

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Proteomic landscape of histiocytic neoplasms: Advancing precision biomarkers, molecular mechanism, and targeted therapies

MAPK pathway-driven metabolic-inflammatory axis in AL amyloidosis

Clinical presentation and prognosis in erdheim-chester disease: Analysis of an international cohort of 1044 patients within the ecdga network

Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

Deciphering the Epigenetic Landscape in Histiocytic Neoplasms

Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Non-Coding RNAs Regulate Novel Signaling Pathways in AL Amyloidosis That Are Targetable By BCL2, PI3K and MEK Inhibitors

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

The Role of Non-Coding RNAs in the Pathogenesis of AL Amyloidosis

A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Eltrombopag for Enhancement of Platelet Engraftment in Patients Undergoing Allogeneic Cord Blood Transplantation

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Bendamustine for Patients with Indolent Lymphoma an Updated Meta-Analysis of Randomized Controlled Trials (RCT)

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only